Skip to main content
. 2024 Jan 17;121(4):e2318093121. doi: 10.1073/pnas.2318093121

Fig. 2.

Fig. 2.

MG-002 significantly and selectively impairs breast cancer cell growth and viability. (A) Time of MDA-MB-231 cells to enter mitosis following release from DNA synthesis block. Release was performed in the presence of DMSO or 10 nM of the indicated compounds. The data shows the average of 50 cells ±SD. (B) Activity of CR-1-31B, eFT226, and MG-002 toward three TNBC cells lines (4T1, BT474, MDA-MB-231). Cells were exposed to the indicated concentrations of compound for 2 d (except for BT474 cells where exposure was for 4 d) and viability measured using the SRB assay. n = 3 ±SD. (C) Activity of CR-1-31B, eFT226, and MG-002 toward IMR-90 and MRC-5 immortalized and non-transformed cells. Cells were exposed to the indicated concentrations of compound for 2 d and stained with SRB. n = 3 ±SD. (D) Activity of CR-1-31B, eFT226, and MG-002 toward HUVEC cell line. Cells were exposed to the indicated concentrations of compound for 2 d and then stained with SRB. n = 3 ±SD. (E) Western blot analysis of the indicated proteins in cells exposed to MG-002 (100 nM), CR-1-31B (100 nM), or doxorubicin (DXR, 0.5 µg/mL) for 24 h.